Detalhe da pesquisa
1.
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.
Hepatology
; 69(6): 2349-2363, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30693573
2.
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
Br J Clin Pharmacol
; 84(5): 961-971, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29345798
3.
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Antimicrob Agents Chemother
; 61(12)2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28971875
4.
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Transpl Infect Dis
; 19(3)2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28295849
5.
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
J Hepatol
; 64(2): 292-300, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26453968
6.
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
J Antimicrob Chemother
; 71(1): 244-50, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26483516
7.
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
J Gastroenterol Hepatol
; 31(5): 912-20, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-26777137
8.
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Ann Hepatol
; 15(4): 512-23, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27236150
9.
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
J Hepatol
; 62(5): 1047-55, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25596313
10.
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 384(9941): 414-26, 2014 Aug 02.
Artigo
Inglês
| MEDLINE | ID: mdl-24907224
11.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet
; 384(9941): 403-13, 2014 Aug 02.
Artigo
Inglês
| MEDLINE | ID: mdl-24907225
12.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lancet
; 384(9956): 1756-65, 2014 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25078309
13.
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Gastroenterology
; 146(7): 1669-79.e3, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24602923
14.
Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Clin Infect Dis
; 59(11): 1579-87, 2014 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25192745
15.
Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
Clin Pharmacokinet
; 62(11): 1533-1550, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37776485
16.
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis.
Clin Pharmacokinet
; 60(9): 1239-1250, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33914285
17.
Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.
J Clin Pharmacol
; 61(10): 1344-1355, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33991350
18.
Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.
AAPS J
; 20(6): 111, 2018 10 22.
Artigo
Inglês
| MEDLINE | ID: mdl-30350297
19.
Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.
AAPS J
; 21(1): 1, 2018 10 24.
Artigo
Inglês
| MEDLINE | ID: mdl-30377854
20.
Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.
Clin Pharmacokinet
; 56(7): 781-792, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27896690